Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 CongressNewsfile Corp • 11/17/25
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateNewsfile Corp • 11/13/25
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762Newsfile Corp • 11/07/25
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award ProgramNewsfile Corp • 11/07/25
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross ProceedsNewsfile Corp • 11/03/25
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer TrialNewsfile Corp • 11/03/25
Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent DirectorNewsfile Corp • 10/31/25
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceNewsfile Corp • 09/03/25
Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateNewsfile Corp • 08/14/25
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross ProceedsNewsfile Corp • 07/25/25
Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth CohortNewsfile Corp • 07/25/25
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug SubstanceNewsfile Corp • 07/25/25
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation CohortNewsfile Corp • 06/25/25
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesNewsfile Corp • 06/24/25
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA PortfolioNewsfile Corp • 06/06/25
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor ConferenceNewsfile Corp • 05/19/25
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateNewsfile Corp • 05/15/25
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical TrialNewsfile Corp • 05/07/25
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next DoseZacks Investment Research • 04/10/25
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation CohortNewsfile Corp • 04/09/25
Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894Newsfile Corp • 04/03/25
Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business UpdateNewsfile Corp • 03/31/25
American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual MeetingNewsfile Corp • 03/10/25